Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for obesity - adults]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Anorectal biofeedback therapy in primary constipation]
2022	Ontario Health	Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Neurophysiological facial nerve monitoring during parotid gland surgery]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: high-dose vitamin C injections for cancer patients in Quebec]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lutetium 177 PSMA in patients with prostate cancer]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022	Ontario Health	Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vagus nerve stimulation for drug-resistant epilepsy]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of adults with non-infectious uveitis
2022	Ontario Health	Genetic testing for familial hypercholesterolemia
2022	NIHR Health Technology Assessment programme	Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022	Ontario Health	Pre-surgical nasal decolonization of staphylococcus aureus
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sialendoscopy for obstructive salivary gland disease]
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways and structures: an updated scoping review
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fluorodopa PET scanning in Parkinson’s disease]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022	NIHR Health Technology Assessment programme	Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Corneal collagen crosslinking with riboflavin in keratoconus]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022	NIHR Health Services and Delivery Research programme	Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Antiangiogenic drugs in refractory age-related macular degeneration]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2021	Scottish Medicines Consortium (SMC)	Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Crizanlizumab for preventing sickle cell crises in sickle cell disease. NICE technology appraisal guidance 743
2021	Scottish Medicines Consortium (SMC)	Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021	Health Technology Wales (HTW)	Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021	NIHR Health Technology Assessment programme	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
2021	Belgian Health Care Knowledge Centre (KCE)	Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	National Institute for Health and Care Excellence (NICE)	NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways: a systematic review
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	WorkSafeBC	Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021	Center for Drug Evaluation (CDE)	Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021	WorkSafeBC	Acupuncture or massage therapy as treatment for occipital neuralgia
2021	National Institute for Health and Care Excellence (NICE)	Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Center for Drug Evaluation (CDE)	Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021	Health Technology Wales (HTW)	Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021	NIHR Health Technology Assessment programme	Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751
2021	Norwegian Institute of Public Health (NIPH)	[Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for TAVI]
2021	National Institute for Health and Care Excellence (NICE)	Belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE technology appraisal guidance 752
2021	Andalusian Health Technology Assessment Area (AETSA)	[18F-FDG in myocardial viability for revascularization]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021	National Institute for Health and Care Excellence (NICE)	Cenobamate for treating focal onset seizures in epilepsy. NICE technology appraisal guidance 753
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021	National Institute for Health and Care Excellence (NICE)	Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome. NICE technology appraisal guidance 754
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021	National Institute for Health and Care Excellence (NICE)	Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer; does the use of fusion biopsy lead to better treatment results compared to the use of conventional diagnostic procedures?]